Clinical utility of the pan-immune-inflammation value in breast cancer patients

Xiaoyan Qi; Xiaoyan Qi; Boyang Qiao; Tingting Song; Dan Huang; Hui Zhang; Yang Liu; Qi Jin; Ming Yang; Delong Liu

doi:10.3389/fonc.2023.1223786

Frontiers in Oncology (Aug 2023)

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Xiaoyan Qi,
Xiaoyan Qi,
Boyang Qiao,
Tingting Song,
Dan Huang,
Hui Zhang,
Yang Liu,
Qi Jin,
Ming Yang,
Delong Liu

Affiliations

Xiaoyan Qi: Department of Breast Surgery, Liaoning Cancer Hospital & Institution, Shenyang, Liaoning, China
Xiaoyan Qi: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Boyang Qiao: School of Pharmaceutical Sciences, Wuhan University, Wuhan, China
Tingting Song: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Dan Huang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Hui Zhang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Yang Liu: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Qi Jin: Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China
Ming Yang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
Delong Liu: Department of Thoracic Surgery, Liaoning Cancer Hospital & Institution, Shenyang, Liaoning, China

DOI: https://doi.org/10.3389/fonc.2023.1223786
Journal volume & issue: Vol. 13

Abstract

Read online

BackgroundThe newly discovered pan-immune-inflammation value (PIV) has been illustrated to have good prognostic value for cancer patient prognosis. However, the prognostic usefulness of PIV in breast cancer patients is unknown. As a result, to aid the clinic in providing a distinctive and trustworthy biomarker to better assess breast cancer patient’s prognosis, we conducted this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients.MethodsWe conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to April 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis.ResultsA total of eight articles, involving 2953 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 2.045, 95% CI: 1.355-3.086, P = 0.001) and PFS (HR: 1.466, 95% CI: 1.163-1.848, P = 0.001). Besides, the PIV value was negatively correlated with the efficacy of neoadjuvant chemotherapy. Sensitivity analysis showed that the results of this study were reliable and stable.ConclusionsPIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords